Difference between revisions of "WWOX-AS1"
Jiabao Cao (talk | contribs) |
Jiabao Cao (talk | contribs) |
||
| Line 6: | Line 6: | ||
RP11-190D6.2<ref name="ref1" /> | RP11-190D6.2<ref name="ref1" /> | ||
===Characteristics=== | ===Characteristics=== | ||
| − | + | Based on the data from USCS database website, lncRNA RP11-190D6.2 is the antisense transcript of protein-coding gene WW domain-containing oxidoreductase (WWOX). <ref name="ref1" /> | |
| − | |||
| − | = | ||
| − | |||
===Function=== | ===Function=== | ||
| + | RP11-190D6.2 overexpression results in the increase of WWOX expression, whereas its knockdown leads to the decrease of WWOX expression. In addition, the RP11-190D6.2 overexpression and knockdown experiments reveals that RP11-190D6.2 overexpression inhibits proliferation, migration, and invasion abilities in HO8910-PM cells, whereas RP11-190D6.2 knockdown in HEY-A8 cells has the opposite effect<ref name="ref1" /> | ||
===Regulation=== | ===Regulation=== | ||
| − | + | RP11-190D6.2 is restored by 5-aza-2′-deoxycytidine treatment in Epithelial ovarian cancer(EOC).<ref name="ref1" /> | |
===Diseases=== | ===Diseases=== | ||
| − | + | Epithelial ovarian cancer (EOC).<ref name="ref1" /> | |
| − | ===Expression=== | + | |
| − | + | ===Expression== | |
| + | Compared with the matched nontumor tissues, the expression level of RP11-190D6.2 in tumor tissues is markedly decreased. Meanwhile, the expression of RP11-190D6.2 is remarkably downregulated in tumors with higher Federation of Gynecology and Obstetrics stage (III/IV) compared with tumors with lower FIGO stage(I/II). In addition, the RP11-190D6.2 expression is positively correlated with WWOX expression(R=0.45519, | ||
| + | P<0.00777).<ref name="ref1" /> | ||
===Sequence=== | ===Sequence=== | ||
Revision as of 02:52, 24 August 2017
Contents
Annotated Information
Name
WWOX-AS1:WWOX antisense RNA 1
RP11-190D6.2[1]
Characteristics
Based on the data from USCS database website, lncRNA RP11-190D6.2 is the antisense transcript of protein-coding gene WW domain-containing oxidoreductase (WWOX). [1]
Function
RP11-190D6.2 overexpression results in the increase of WWOX expression, whereas its knockdown leads to the decrease of WWOX expression. In addition, the RP11-190D6.2 overexpression and knockdown experiments reveals that RP11-190D6.2 overexpression inhibits proliferation, migration, and invasion abilities in HO8910-PM cells, whereas RP11-190D6.2 knockdown in HEY-A8 cells has the opposite effect[1]
Regulation
RP11-190D6.2 is restored by 5-aza-2′-deoxycytidine treatment in Epithelial ovarian cancer(EOC).[1]
Diseases
Epithelial ovarian cancer (EOC).[1]
=Expression
Compared with the matched nontumor tissues, the expression level of RP11-190D6.2 in tumor tissues is markedly decreased. Meanwhile, the expression of RP11-190D6.2 is remarkably downregulated in tumors with higher Federation of Gynecology and Obstetrics stage (III/IV) compared with tumors with lower FIGO stage(I/II). In addition, the RP11-190D6.2 expression is positively correlated with WWOX expression(R=0.45519, P<0.00777).[1]
Sequence
>XR_429776.2 PREDICTED: Homo sapiens uncharacterized LOC102724047 (LOC102724047), transcript variant X2, ncRNA
000081 TGGAACAAGG ATGAGGCAGG CAGGCTCTGA TAGCAACAGG AGGAAGCAGA CCAAGGAGGG AGAGAAAGGA AGGCAGAGAA 000160
000161 GGGGAAAAAA AAACACAAAT GATAATAATA GATGCTGACA TTTACGGAGC ACTTACTATG TGCTGGGAAC CATGCTGACG 000240
000241 GCACACCGAA TCCACTGAAC AGATCTCTTT GGGTTTTGGA ATAACAAAAA AGGGACTGTA CATGGATATT TCCAAGCTGG 000320
000321 AACCGAGGCA CTTTCTAGAC GAAGGCAGCC TTATCCCCAG GAGATGATTG AAAATGTAAG AACTATTCTG AGCCTGCAGG 000400
000401 CCATAGCCAA AGAGGACCTA CTGTTAAGTT TTCAAGACCA CCCAGAAAGA AATTTGAAGT TGGGTTTATA TCCTTAATCC 000480
000481 CTCAGTTAGA AAAAAAAGAA AAGTGAAGAA ACTGCATCTC CAAGATCCTG CTATATCAAC TTCAGTTTTT TGAAGTTAAA 000560
000561 TTTGATTTTT AAATCCCTTG GCTGATGAGA CCTGTGTGGG TTTTTTTTTG TTGTTTTTTT GTTTTGTTTT GTTTTGTTTT 000640
000641 ATCATTGTAC CTCTATTTTA AAAATAGAGA CTTGTGGTTC TTTTTCCAAA AGCAGTCCAA CAGAAAGTGA ATGGTGGTCA 000720
000721 ATGCATAATA AAATGAGAGT TACCTTTTGA
Labs working on this lncRNA
- Department of Oncology, The Fifth Hospital of Wuhan.
